Leukemia - Issue - nature.com science feeds

How to manage primary amyloidosis

M A Gertz — 2012-02-08

How to manage primary amyloidosis

Leukemia 26, 191 (February 2012). doi:10.1038/leu.2011.219

Author: M A Gertz

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma

N W C J van de Donk — 2012-02-08

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma

Leukemia 26, 199 (February 2012). doi:10.1038/leu.2011.214

Authors: N W C J van de Donk, S Kamps, T Mutis & H M Lokhorst

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy

P J Shami — 2012-02-08

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy

Leukemia 26, 214 (February 2012). doi:10.1038/leu.2011.217

Authors: P J Shami & M Deininger

Absence of IL-12Rβ2 in CD33+CD38+ pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice

E Ferretti — 2012-02-08

Absence of IL-12Rβ2 in CD33+CD38+ pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice

Leukemia 26, 225 (February 2012). doi:10.1038/leu.2011.213

Authors: E Ferretti, D Montagna, E Di Carlo, C Cocco, D Ribatti, E Ognio, C Sorrentino, D Lisini, A Bertaina, F Locatelli, V Pistoia & I Airoldi

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

K C Goh — 2012-02-08

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

Leukemia 26, 236 (February 2012). doi:10.1038/leu.2011.218

Authors: K C Goh, V Novotny-Diermayr, S Hart, L C Ong, Y K Loh, A Cheong, Y C Tan, C Hu, R Jayaraman, A D William, E T Sun, B W Dymock, K H Ong, K Ethirajulu, F Burrows & J M Wood

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors

S Negrotto — 2012-02-08

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors

Leukemia 26, 244 (February 2012). doi:10.1038/leu.2011.207

Authors: S Negrotto, K P Ng, A M Jankowska, J Bodo, B Gopalan, K Guinta, J C Mulloy, E Hsi, J Maciejewski & Y Saunthararajah

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells

J F de Vries — 2012-02-08

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells

Leukemia 26, 255 (February 2012). doi:10.1038/leu.2011.206

Authors: J F de Vries, C M Zwaan, M De Bie, J S A Voerman, M L den Boer, J J M van Dongen & V H J van der Velden

ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy

D Bhojwani — 2012-02-08

ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy

Leukemia 26, 265 (February 2012). doi:10.1038/leu.2011.227

Authors: D Bhojwani, D Pei, J T Sandlund, S Jeha, R C Ribeiro, J E Rubnitz, S C Raimondi, S Shurtleff, M Onciu, C Cheng, E Coustan-Smith, W P Bowman, S C Howard, M L Metzger, H Inaba, W Leung, W E Evans, D Campana, M V Relling & C-H Pui

Endogenous knockdown of survivin improves chemotherapeutic response in ALL models

D J Morrison — 2012-02-08

Endogenous knockdown of survivin improves chemotherapeutic response in ALL models

Leukemia 26, 271 (February 2012). doi:10.1038/leu.2011.199

Authors: D J Morrison, L E Hogan, G Condos, T Bhatla, N Germino, N P Moskowitz, L Lee, D Bhojwani, T M Horton, I Belitskaya-Levy, L M Greenberger, I D Horak, S A Grupp, D T Teachey, E A Raetz & W L Carroll

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2

A V Purandare — 2012-02-08

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2

Leukemia 26, 280 (February 2012). doi:10.1038/leu.2011.292

Authors: A V Purandare, T M McDevitt, H Wan, D You, B Penhallow, X Han, R Vuppugalla, Y Zhang, S U Ruepp, G L Trainor, L Lombardo, D Pedicord, M M Gottardis, P Ross-Macdonald, H de Silva, J Hosbach, S L Emanuel, Y Blat, E Fitzpatrick, T L Taylor, K W McIntyre, E Michaud, C Mulligan, F Y Lee, A Woolfson, T L Lasho, A Pardanani, A Tefferi & M V Lorenzi

Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia

F Damm — 2012-02-08

Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia

Leukemia 26, 289 (February 2012). doi:10.1038/leu.2011.200

Authors: F Damm, T Bunke, F Thol, B Markus, K Wagner, G Göhring, B Schlegelberger, G Heil, C W M Reuter, K Püllmann, R F Schlenk, K Döhner, M Heuser, J Krauter, H Döhner, A Ganser & M A Morgan

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib

D Marin — 2012-02-08

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib

Leukemia 26, 296 (February 2012). doi:10.1038/leu.2011.180

Authors: D Marin, I H Gabriel, S Ahmad, L Foroni, H de Lavallade, R Clark, S O'Brien, R Sergeant, C Hedgley, D Milojkovic, J S Khorashad, M Bua, A Alsuliman, A Khoder, K Stringaris, N Cooper, J Davis, J M Goldman, J F Apperley & K Rezvani

C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells

Y Satoh — 2012-02-08

C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells

Leukemia 26, 303 (February 2012). doi:10.1038/leu.2011.202

Authors: Y Satoh, I Matsumura, H Tanaka, H Harada, Y Harada, K Matsui, M Shibata, M Mizuki & Y Kanakura

Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia

S Stevanović — 2012-02-08

Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia

Leukemia 26, 312 (February 2012). doi:10.1038/leu.2011.222

Authors: S Stevanović, M Griffioen, B A Nijmeijer, M L J van Schie, A N Stumpf, C E Rutten, R Willemze & J H F Falkenburg

Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1

R C T McKenzie — 2012-02-08

Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1

Leukemia 26, 323 (February 2012). doi:10.1038/leu.2011.198

Authors: R C T McKenzie, C L Jones, I Tosi, J A Caesar, S J Whittaker & T J Mitchell

Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b+/F4/80+ myeloid cell recruitment

M Ishihara — 2012-02-08

Plasmin inhibitor reduces T-cell lymphoid tumor growth by suppressing matrix metalloproteinase-9-dependent CD11b+/F4/80+ myeloid cell recruitment

Leukemia 26, 332 (February 2012). doi:10.1038/leu.2011.203

Authors: M Ishihara, C Nishida, Y Tashiro, I Gritli, J Rosenkvist, M Koizumi, Y Okaji, R Yamamoto, H Yagita, K Okumura, M Nishikori, K Wanaka, Y Tsuda, Y Okada, H Nakauchi, B Heissig & K Hattori

MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma

V Ramakrishnan — 2012-02-08

MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma

Leukemia 26, 340 (February 2012). doi:10.1038/leu.2011.192

Authors: V Ramakrishnan, S Ansell, J Haug, D Grote, T Kimlinger, M Stenson, M Timm, L Wellik, T Halling, S V Rajkumar & S Kumar

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial

K D Boyd — 2012-02-08

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial

Leukemia 26, 349 (February 2012). doi:10.1038/leu.2011.204

Authors: K D Boyd, F M Ross, L Chiecchio, G P Dagrada, Z J Konn, W J Tapper, B A Walker, C P Wardell, W M Gregory, A J Szubert, S E Bell, J A Child, G H Jackson, F E Davies & G J Morgan

Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide

G Göhring — 2012-02-08

Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide

Leukemia 26, 356 (February 2012). doi:10.1038/leu.2011.193

Authors: G Göhring, K Lange, W Hofmann, K V Nielsen, E Hellström-Lindberg, L Roy, M Morgan, H Kreipe, G Büsche, A Giagounidis & B Schlegelberger

High Epstein–Barr virus-specific T-cell counts are associated with near-zero likelihood of acute myeloid leukemia relapse after hematopoietic cell transplantation

M Hoegh-Petersen — 2012-02-08

High Epstein–Barr virus-specific T-cell counts are associated with near-zero likelihood of acute myeloid leukemia relapse after hematopoietic cell transplantation

Leukemia 26, 359 (February 2012). doi:10.1038/leu.2011.195

Authors: M Hoegh-Petersen, S Sy, A Ugarte-Torres, T S Williamson, M Eliasziw, A Mansoor, Y Liu, S Liu, P Podgorny, F Khan, P R Duggan, D A Stewart, J A Russell & J Storek

Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML

A van der Jagt — 2012-02-08

Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML

Leukemia 26, 362 (February 2012). doi:10.1038/leu.2011.201

Authors: A van der Jagt, J Muirhead, J F Seymour, K F Bradstock, E Paul & A Wei

T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells

K Mihara — 2012-02-08

T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells

Leukemia 26, 365 (February 2012). doi:10.1038/leu.2011.205

Authors: K Mihara, J Bhattacharyya, A Kitanaka, K Yanagihara, T Kubo, Y Takei, H Asaoku, Y Takihara & A Kimura

DNA methylation pattern is altered in childhood T-cell acute lymphoblastic leukemia patients as compared with normal thymic subsets: insights into CpG island methylator phenotype in T-ALL

M D Kraszewska — 2012-02-08

DNA methylation pattern is altered in childhood T-cell acute lymphoblastic leukemia patients as compared with normal thymic subsets: insights into CpG island methylator phenotype in T-ALL

Leukemia 26, 367 (February 2012). doi:10.1038/leu.2011.208

Authors: M D Kraszewska, M Dawidowska, N S D Larmonie, M Kosmalska, Ł Sędek, M Szczepaniak, W Grzeszczak, A W Langerak, T Szczepański & M Witt

Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model

I H I M Hollink — 2012-02-08

Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model

Leukemia 26, 371 (February 2012). doi:10.1038/leu.2011.210

Authors: I H I M Hollink, Q Feng, A A Danen-van Oorschot, S T C J M Arentsen-Peters, L J Verboon, P Zhang, V de Haas, D Reinhardt, U Creutzig, J Trka, R Pieters, M M van den Heuvel-Eibrink, J Wang & C M Zwaan

Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population

T D Shanafelt — 2012-02-08

Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population

Leukemia 26, 373 (February 2012). doi:10.1038/leu.2011.211

Authors: T D Shanafelt, N E Kay, K G Rabe, T G Call, C S Zent, S M Schwager, J F Leis, D F Jelinek, S L Slager & C A Hanson

Comparison of childhood leukemia initiating cell populations in NOD/SCID and NSG mice

P Diamanti — 2012-02-08

Comparison of childhood leukemia initiating cell populations in NOD/SCID and NSG mice

Leukemia 26, 376 (February 2012). doi:10.1038/leu.2011.212

Authors: P Diamanti, C V Cox & A Blair